Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1 crawled date : 2021 - 10 - 21 save search
ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid LeukemiaSecond study of evorpacept in patients with myeloid malignancies
Published: 2021-10-21 (Crawled : 14:00) - biospace.com/
ALXO M | $16.22 4.65% 4.56% 440K
|
Commercial Services
|
| O: -0.2%
H: 2.32%
C: -1.72%
myeloid leukemia phase 1 leukemia
Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
MTNB | $0.1818 0.17% 2.04% 520K
|
Health Technology
|
| O: 0.0%
H: 4.39%
C: 2.63%
biopharma phase 1 potential drug iot phase 2 phase 3
Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis
Published: 2021-10-21 (Crawled : 11:00) - biospace.com/
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 9.3%
H: 12.98%
C: 0.43%
ongoing gene therapies phase 1 gene therapy positive therapy biomarkers
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
RILY | $29.75 36.97% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.